Luye Pharma Group (LYPHF) Stock Price, News & Analysis

Company Overview

Luye Pharma Group Limited is a China-based pharmaceutical company engaged in the research, development, manufacturing and commercialization of prescription medicines. The company focuses on innovative drugs, specialty pharmaceuticals and selected generic products, with activities spanning drug discovery, clinical development, production and sales.

Its product portfolio includes treatments in areas such as central nervous system disorders, oncology, cardiovascular and metabolic diseases, and gastrointestinal conditions. Luye has developed and commercialized products using technologies including transdermal delivery, long-acting injectable formulations and microsphere-based drug delivery systems. Its central nervous system portfolio includes medicines for conditions such as schizophrenia, depression and dementia.

Founded in 1997, Luye Pharma is headquartered in China and has expanded its commercial and research activities internationally. The company serves markets in China and has a presence or operations across regions including North America, Europe and parts of Asia-Pacific. Luye Pharma was listed on the Hong Kong Stock Exchange in 2014. Liu Dianbo, the company’s founder, has served as chairman.

Key Stats

• Today's Range: $0.27 to $0.27
• 50-Day Range: $0.27 to $0.27
• 52-Week Range: $0.20 to $0.33
• Volume: N/A
• Average Volume: 1.23 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:LYPHF
• CIK: N/A
• Web: www.luye.cn
• Phone: +865356717618
• Fax: N/A
• Employees: 5,221
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A